Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN2 | P17655 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 16/20 | 0.44 |
| ▸ | MMP7 | P09237 | 16/20 | 0.44 |
| ▸ | MMP3 | P08254 | 15/20 | 0.44 |
| ▸ | MMP1 | P03956 | 14/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8206145 | 0.97 | MMP2 (0.44) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8209145 | 0.92 | CPB2 (0.42) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8205387 | 0.89 | MMP2 (0.49) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL12943170 | 0.86 | MMP2 (0.49) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8208869 | 0.85 | F2 (0.35) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8211181 | 0.85 | F2 (0.35) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8205365 | 0.84 | CAPN2 (0.49) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8213641 | 0.84 | CAPN2 (0.34) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL8208876 | 0.83 | CAPN2 (0.50) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL12943111 | 0.82 | CAPN2 (0.36) | CAPN2MMP2MMP7MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |